Target: CD14.
Specificity: Detects human CD14. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Atibuclimab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: RUO atibuclimab is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It acts as a pattern recognition receptor for bacterial cell wall components in gram-positive and negative bacteria. CD14 antibody action stimulates a pro-inflammatory cytokine cascade often associated with inflammation in sepsis. Atibuclimab neutralization of this antibody results in the inhibition of TNF-a, IL-6 and IL-10, dampening systemic inflammatory responses. Atibuclimab also delays the release of sTNFR(1) and IL-1ra.
Concentration: 5mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
